Chronic inflammation in the tumor microenvironment and evasion of the antitumor effector
immune response are two of the emerging hallmarks required for oncogenesis and cancer …

Passive immunotherapy, including adoptive T-cell therapy and antibody therapy, has shown
encouraging results in cancer treatment lately. However, active immunotherapy of solid …

Cancer immunotherapy is demonstrating impressive clinical benefit in different malignancies
and clinical oncologists are increasingly turning their attention to immune-oncology. It is now …

The dichotomy of immunology into innate and adaptive immunity has created conceptual
barriers in appreciating the intrinsic two-way interaction between immune cells. An emerging …

Chronic inflammation increases the risk of several cancers, including gastric, colon, and
hepatic cancers. Conversely, tumors, similar to tissue injury, trigger an inflammatory …

In many settings, tumor-associated inflammation, supported mainly by innate immune cells,
contributes to tumor growth. Initial innate activation triggers secretion of inflammatory …

Immunity to infectious agents involves a coordinated response of innate and adaptive
immune cells working in concert, with many feed-forward and regulatory interactions …

The recognition of the important role of cancer immunity in tumors has led to the introduction
of immunotherapeutic strategies. Most of the immunomodulatory approaches currently being …

The presence of inflammatory immune cells in human tumors raises a fundamental question
in oncology: How do cancer cells avoid the destruction by immune attack? In principle, tumor …

The development of cancer immunotherapies has been guided by advances in our
understanding of the dynamics between tumor cells and immune populations. An emerging …